ライフサイエンスコーパス: naltrindole

1 Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2)) and naltrindole.

2 kephalin on Na(V)1.7 levels was prevented by naltrindole.

3 y DPDPE were blocked by the delta antagonist naltrindole.

4 t genes were either up- or down-regulated by naltrindole.

5 t that rescued the deficit in PIT induced by naltrindole.

6 vely, but not the delta-selective antagonist naltrindole.

7 otency that is only partially antagonized by naltrindole.

8 a antagonist, albeit with lower potency than naltrindole.

9 the delta-1 and delta-2 receptor antagonist naltrindole.

10 R, bound to the subtype-selective antagonist naltrindole.

11 d selective delta-opioid receptor antagonist naltrindole (1) and the spiroindanyl analogues 2 and 3,

12 gues of the delta opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzylo

13 an the conformationally constrained ligands, naltrindole (1, NTI) and 7-(spiroindanyl)oxymorphone (2,

14 es (7 and 9) of the delta-selective ligands, naltrindole (1, NTI) and spiroindanyloxymorphone (2, SIO

15 mine, 0.1-20 microgram), or delta-selective (naltrindole, 1-20 microgram) opioid receptor antagonists

16 DOR inhibition with naltrindole (10 microM) led to significant injury in nor

17 Naltrindole (10 microM), a delta-opioid receptor antagon

18 Naltrindole (10-100 microM) decreased amphetamine-evoked

19 ndole moiety in the delta-opioid antagonist, naltrindole (2, NTI), was employed as a scaffold to hold

20 xone (5 mg/kg, sc), an opioid antagonist, or naltrindole (5 mg/kg, sc), a delta antagonist, blocked t

21 he delta opioid receptor-specific antagonist naltrindole (5 microg) did not.

22 e selective delta-opioid receptor antagonist naltrindole (500 nM).

23 AMGO: a mu-opioid selective agonist) and [3H]naltrindole (a delta-opioid selective antagonist) reveal

24 Naltrindole, a delta receptor antagonist, inhibited the

25 Pre-treatment prior to the swim with naltrindole, a selective delta-opioid receptor antagonis

26 Naltrindole, a selective DOR antagonist, abolished the i

27 Naltrindole, a selective DOR antagonist, abolished the i

28 the use of the selective radioligands [(3)H]naltrindole and [(3)H]norbinaltorphimine (nor-BNI) in co

29 d robust CoMFA models, a sizable data set of naltrindole and naltrexone analogues was assembled by po

30 osphorylated p38 immunoreactivity induced by naltrindole and reduced the neuronal injury.

31 can be labeled with the opiate alkaloid [3H]naltrindole and show greatly increased affinities toward

32 s (KDAN series) containing delta-antagonist (naltrindole) and kappa(1)-agonist (ICI-199,441) pharmaco

33 in (100, 500 microM), reversed the effect of naltrindole, confirming that delta receptors mediated th

34 e Akt/PKB signaling pathway, suggesting that naltrindole could be a potential lead for the developmen

35 orphine on all parameters measured, however, naltrindole (delta-selective antagonist, 2 micrograms/2

36 ,Pen7 amide or the delta-receptor antagonist naltrindole failed to block NSIA.

37 Under these conditions, naltrindole had no effect on the calcium-independent com

38 Lidocaine and naltrindole had no effect when injected into the dorsola

39 he side chain in 5'-substituted analogues of naltrindole has been further explored with the synthesis

40 rphine on GTP binding cannot be inhibited by naltrindole in the wild-type receptor.

41 and microscopic analyses clearly showed that naltrindole induced apoptosis in SCLC cells.

42 RNA interference experiments confirmed that naltrindole-induced cell death was associated with the A

43 m classical delta-opioid antagonists such as naltrindole into potent beta-arrestin-biased agonists.

44 Infusion of naltrindole into the accumbens shell abolished transfer

45 r-Pen-Thr-NH(2) (CTAP) or the DOR antagonist naltrindole into the core or shell subregions of the nuc

46 Multiple microinfusions of naltrindole into the dorsal striatum or multiple systemi

47 infusion of SCH-23390 and the DOR antagonist naltrindole into the NAc-S also abolished PIT.

48 Together, these results show that naltrindole is a new inhibitor of the Akt/PKB signaling

49 ltrexamine (BFNA) or the delta 2 antagonist, naltrindole isothiocyanate (Ntii) in the periaqueductal

50 exone), mu (beta-funaltrexamine) and delta2 (naltrindole isothiocyanate) opioid antagonists administe

51 l (naltrexone), mu, kappa, delta1 or delta2 (naltrindole isothiocyanate) opioid antagonists into the

52 u(5), Cys(6)]-enkephalin (DALCE)), delta(2) (naltrindole isothiocyanate) or kappa(1) (nor-binaltorpha

53 6]-enkephalin: 10-40 micrograms) or delta 2 (naltrindole isothiocyanate: 20 micrograms) opioid subtyp

54 receptor affinity and antagonist potency of naltrindole (Ki = 0.29 nM, Ke = 0.49 nM).

55 Naltrindole (NTD) alone elicited a 75 +/- 30% increase i

56 c indium-labeled DOTA and DO3A conjugates of naltrindole (NTI) that are suited to in vivo studies of

57 delta opiate receptor-selective antagonists naltrindole (NTI), 7-benzylidenenaltrexone (BNTX) or nal

58 The delta-selective opioid antagonist naltrindole (NTI), as well as the kappa-selective opioid

59 ociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-an

60 ere found to be more mu/delta-selective than naltrindole (NTI).

61 A, mu), nor-binaltorphamine (NBNI, kappa) or naltrindole (NTI, delta).

62 t the delta-opioid receptor (DOR) antagonist naltrindole (NTI; 1 mum) did not, implicating MORs in fe

63 kappa (nor-binaltorphamine: NBNI) or delta (naltrindole: NTI) opioid antagonists in the VTA, and cor

64 is of the selective delta opioid antagonist, naltrindole, on extracellular striatal glutamate levels

65 e selective delta-opioid receptor antagonist naltrindole only partially blocked the effect of MMP-220

66 ckade of delta-opioid or VIP receptors using naltrindole or VIP6-28, respectively antagonized the VIP

67 Strikingly, chronic blockade of DOR using naltrindole partially improved motor coordination and no

68 Along with the injury, either by hypoxia or naltrindole, phosphorylated p38 increased in a major way

69 sion of the delta-opioid receptor antagonist naltrindole prevented tolerance development to morphine

70 iatum or multiple systemic administration of naltrindole reduces ethanol consumption, and following t

71 Indolic N-benzylation of naltrindole reportedly extends the duration of delta-opi

72 Most strikingly, the same mutant exhibits naltrindole-sensitive etorphine-stimulated [35S]guanosin

73 her experiments revealed that the binding of naltrindole to delta opioid receptors could increase the

74 Furthermore, naltrindole treatment not only reduced the phosphorylati

75 Naltrindole treatment reduced constitutive phosphorylati

76 h the sensitivity of the three cell lines to naltrindole treatment.

77 The delta-opioid antagonist naltrindole was inactive in both treatment groups.

78 The Kd value for naltrindole was likewise unaffected by age.

79 rphinans, a range of 4-phenolic analogues of naltrindole were prepared and evaluated in in vitro assa

80 gonists (naltrexone, norbinaltorphimine, and naltrindole) were substantially less effective in produc

81 Here we report that naltrindole, which has been used as a classic delta opio